INBS INBS
Company Profile ↓Company Overview
INBS (INBS) is a publicly traded company listed on with a market capitalization of $1.31M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 74.5% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.09.
Recent Developments
- Jun 2025 Revenue of $3.05M (-1.9% YoY); net profit $-10.57M.
- Trailing 12 Months Year-on-year growth — revenue -1.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 74.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 74.48% |
| 1 Year: | -1.90% |
Stock Price Performance
| 1 Year: | -88.22% |
| 6 Months: | -75.84% |
| 3 Months: | -26.03% |
| 1 Month: | -19.73% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)40.07 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 74.5% over 5 years.
CONS
- Trading 90.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 34.29K | - | - | 192.50K | 311.32K | 356.68K | 457.06K | 796.09K | 764.06K | 823.80K | 872.29K | 607.49K | 728.87K | 1.11M | 896.77K | 1.06M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | 244.04K | 33.05K | 232.33K | 199.25K | 178.49K | 346.80K | 223.11K | 341.37K | 518.29K | 459.74K | 535.38K |
| Operating Income | -1.70M | -28.82K | - | -663.00K | -917.33K | -3.14M | -1.44M | -3.47M | -1.34M | -1.22M | -2.13M | -6.54M | -2.53M | -1.99M | -2.95M | -2.73M | -2.26M | -2.56M | -3.00M | -2.64M | -2.95M |
| Net Income | -1.84M | -112.59K | -1.84M | -1.07M | -1.98M | -3.13M | -1.43M | -3.46M | -1.34M | -1.21M | -420.60K | -6.34M | -2.43M | -1.97M | -2.98M | -2.69M | -2.25M | -2.54M | -2.98M | -2.68M | -2.86M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -1.62 | -5.56 | -68.67 | -12.48 | -2.07 | -1.43 | -0.70 | -4.96 | -4.41 | -0.35 | -2.82 | -1.80 |
| R&D Expense | 494.67K | - | - | - | 341.82K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|
| Revenue | 188.74K | 1.98M | 437.15K | 1.26M | 3.11M | 3.05M |
| Gross Profit | - | - | - | 326.67K | 1.43M | 1.25M |
| Operating Income | -2.86M | -5.57M | -8.34M | -12.60M | -10.28M | -10.64M |
| Net Income | -3.16M | -7.04M | -8.31M | -10.63M | -10.16M | -10.57M |
| Diluted EPS | - | - | -11.33 | -127.00 | -6.38 | -2.00 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Apr 2024 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 2.48M | 21.86M | 12.35M | 10.35M | - | 13.78M | 8.25M |
| Current Assets | - | - | - | 10.87M | 3.86M | - | 8.53M | 4.14M |
| Cash & Equivalents | - | 427.27K | 12.57M | 8.24M | 1.54M | - | 6.30M | 1.02M |
| Inventory | - | - | - | 0 | 979.91K | - | 777.54K | 635.22K |
| Receivables | - | - | - | 0 | 293.86K | - | 429.70K | 594.61K |
| Total Liabilities | - | 7.69M | 6.85M | 5.81M | 6.67M | - | 5.60M | 5.44M |
| Current Liabilities | - | 7.69M | 3.68M | 4.66M | 5.88M | - | 5.45M | 5.35M |
| Long Term Debt | - | - | - | - | 402.86K | 1.65M | - | - |
| Total Debt | - | - | - | 0 | 1.34M | - | 871.44K | 281.81K |
| Total Equity | -3.98M | -5.19M | 15.06M | 6.62M | 3.80M | - | 8.33M | 3.00M |
| Shares Outstanding | - | - | - | 6.20K | 19.42K | - | 345.60K | 732.34K |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -498.62K | -11.30M | -3.36M | -7.38M | -9.57M | -9.68M |
| Investing Cash Flow | -14.00K | - | -880.22K | -694.14K | -221.43K | -231.84K |
| Financing Cash Flow | 733.86K | 23.40M | - | 1.44M | 14.56M | 4.60M |
| Capital Expenditure | - | - | - | - | -221.43K | -231.84K |
| Free Cash Flow | - | - | - | - | -9.79M | -9.91M |
Ratios (Annual)
Figures in %.
| Metric | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | 26.0% | 45.8% | 40.8% |
| Operating Margin % | -1,513.7% | -281.4% | -1,907.1% | -1,002.1% | -330.5% | -348.7% |
| Net Margin % | -1,676.2% | -355.3% | -1,900.1% | -845.9% | -326.4% | -346.2% |
| ROE % | 61.0% | -46.7% | -125.4% | -279.9% | -121.9% | -352.7% |
| ROCE % | 54.8% | -30.7% | -108.4% | -281.7% | -123.5% | -367.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for INBS
15 Operators Used Intelligent Bio Solutions' Drug Test Without Lab Training - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNeWN3MDZhZXpjYTM2cVo4UDktVXUxQTN4VEZ3dzdTbnpKZU1jbER0UXRBNjRtbUt3XzJRYTNRYWFtWmJTLXdVUWtIdWJhdmVwVVJHdzlRazROaXJOQ1h6a3dqeU9IcURzaGFVaVdMVzRSeURsQmlJX3doM25oaTZuOFlvZXNMRmdHWWVLRF…
Intelligent Bio Solutions reports 3,018,188 shares outstanding as of July 31, 2026 - TradingView
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxObnZpZnRXc3lJNUlMMmNlbHlrblZnM3E4SHNDUWxBQW1zRTRPWkhkaTFIc21WcVJubFdxd0VvQXN3UUxsYm94V3oyelp6QVBMZ1hTc2o3V3c4YTU5SWRkUVhTWjZyMmhoc1ZqN1FHZmxhZlh2OWZ5TVNnQjFvTDdJc3BVMHY3eTc5S2p0Wn…
Intelligent Bio Solutions drug screen tested against hand creams and dirt - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQVVN1Rl9nS0xXM2Vadk9fd3RTWVB0MGtEbDNkbldVYTFsOU5WRklGV0Jud2VqYzBZUVhlTmIyUmg1RWNTQWZkTGNtR0JOYXpWVUJPQ1RXYnJzT1hhdkc0Mmh0YkEtdENKamNwTUppR3BrV3BPWWVscDFndmtPLUNnT1E1dk44X3JhZW01Tn…
INBS Stock Reverses Early Gains After First Shipment of Drug Screening Readers Under Syrma Johari MedTech Partnership - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNZzhtUWxxa2RLdjA5Q0lJMEx4SmxnV2lmWXpvelJuNm0xYjQ4RmN5QlY4Nmt4R2dDZFpMSkZhUFhRS1Q1ZG14UUZDRjJabmR6cURfTDBEQUQwaWx4RVIzVVdnalZvQkh5dFNBUU5QaWZaUVU0UTVZRjVVTkFIUXdVckdHZkpRWHpINjZhOH…
INBS|Intelligent Bio Solutions Inc|Price:1.810|Chg%:+0.250 - TradingKey
<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTE1vSGctcjhEUVdjZVFmdEdvZFZERF9nZE96NlF4RUpydEFkMVJJenVCM2tkRUNEV05CeUhDc0EwUXRUUG9rdUExV2hKdV9zTDNpOE52dFc5NkV3Zw?oc=5" target="_blank">INBS|Intelligent Bio Solutions Inc|Price:1.81…
INBS Stock Surges 132.4% on New Manufacturing Partnership - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE43emhjeVBYQVBaLWo1MmNwRDdYZy1ud0YtZGR1cm9SQzVETjd3cGdBd2FYU0x1SjBhVGFvQ05WNjZNLUhlSHZobjRoeUdGOXRabWtqNkhQejktZkhqTEN1RWFVeF9GNkNoekRBU2FSZ0ZERGhFS003MA?oc=5" target="_blank">INBS …
INBS — Frequently Asked Questions
What is the current share price of INBS?
As of 2026-08-05 17:25 PDT, INBS trades at $1.79 on NASDAQ/NYSE. Its 52-week range is $1.55 to $18.80.
What is the market capitalisation of INBS?
INBS has a market capitalisation of $1.31M on NASDAQ/NYSE.
What is the P/E ratio of INBS?
INBS trades at a trailing price-to-earnings (P/E) ratio of -0.90. Its price-to-book (P/B) ratio is 0.44.
Is INBS a good stock to buy?
This page provides a data-driven analysis of INBS, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.